STING1 and neoplasm: In addition, STING agonists can induce a phenotypic shift of macrophages from an M2‐like pro‐tumour state to an M1‐like anti‐tumour state, overcoming diverse layers of immunosuppression initiated by tumour cells and synergizing with PARP inhibitors to suppress the growth of advanced BRCA‐mutant ovarian tumours.